Pulmatrix Q1 2026 net loss narrows to $1.2 million; cash falls to $3.3 million
Pulmatrix reported a first quarter 2026 net loss of $1.2 million, or $0.32 per share, down from $1.8 million, or $0.50 per share, a year earlier. Cash and cash equivalents fell to $3.3 million, and the unaudited financials include going-concern language; the company says its cash is sufficient to fund operations at least through the anticipated closing of its proposed merger with Eos SENOLYTIX, expected in the third quarter of 2026.
Key points
- Net loss of $1.2 million ($0.32 per share) for the three months ended March 31, 2026, versus $1.8 million ($0.50 per share) a year earlier
- General and administrative expenses fell to $1.3 million from $1.8 million, mainly due to Form S-4 costs incurred in the prior-year quarter
- Cash and cash equivalents were $3.3 million at March 31, 2026, down from $4.1 million at December 31, 2025
- Merger agreement with Eos SENOLYTIX signed March 26, 2026; closing anticipated in the third quarter of 2026
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.